DNA repair in cancer: emerging targets for personalized therapy

References

• HoeijmakersJHGenome maintenance mechanisms for preventing cancerNature2001411683536637411357144
   PubMed Web of Science ®Google Scholar
• SweasyJBLangTDiMaioDIs base excision repair a tumor suppressor mechanism?Cell Cycle20065325025916418580
   PubMed Web of Science ®Google Scholar
• GoodeELUlrichCMPotterJDPolymorphisms in DNA repair genes and associations with cancer riskCancer Epidemiol Biomarkers Prev200211121513153012496039
   PubMed Web of Science ®Google Scholar
• FrosinaGCommentary: DNA base excision repair defects in human pathologiesFree Radic Res200438101037105415512792
   PubMed Web of Science ®Google Scholar
• LongleyDBJohnstonPGMolecular mechanisms of drug resistanceJ Pathol2005205227529215641020
   PubMed Web of Science ®Google Scholar
• MadhusudanSHicksonIDDNA repair inhibition: a selective tumour targeting strategyTrends Mol Med2005111150351116214418
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature2005434703591391715829966
   PubMed Web of Science ®Google Scholar
• LoebLASpringgateCFBattulaNErrors in DNA replication as a basis of malignant changesCancer Res1974349231123214136142
   PubMed Web of Science ®Google Scholar
• LambrosMBNatrajanRGeyerFCPPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization studyMod Pathol201023101334134520543821
   PubMed Web of Science ®Google Scholar
• EkerAPQuayleCChavesIvan der HorstGTDNA repair in mammalian cells: direct DNA damage reversal: elegant solutions for nasty problemsCell Mol Life Sci200966696898019153659
   PubMed Web of Science ®Google Scholar
• LordCJAshworthABiology-driven cancer drug development: back to the futureBMC Biol201083820385032
   PubMed Web of Science ®Google Scholar
• NatrajanRWeigeltBMackayAAn integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancersBreast Cancer Res Treat2010121357558919688261
   PubMed Web of Science ®Google Scholar
• SancarALindsey-BoltzLAUnsal-KacmazKLinnSMolecular mechanisms of mammalian DNA repair and the DNA damage checkpointsAnnu Rev Biochem200473398515189136
   PubMed Web of Science ®Google Scholar
• FortiniPPascucciBParlantiED’ErricoMSimonelliVDogliottiEThe base excision repair: mechanisms and its relevance for cancer susceptibilityBiochimie200385111053107114726013
   PubMed Web of Science ®Google Scholar
• NilsenHKrokanHEBase excision repair in a network of defence and toleranceCarcinogenesis200122798799811408341
   PubMed Web of Science ®Google Scholar
• IzumiTWiederholdLRRoyGMammalian DNA base excision repair proteins: their interactions and role in repair of oxidative DNA damageToxicology20031931–2436514599767
   PubMed Web of Science ®Google Scholar
• DianovGAllinsonSLBudworthHSleethKMMammalian base excision repairCaldecottKWEukaryotic DNA Damage Surveillance and RepairKluwer Academic/Plenium Publishers2003122
   Google Scholar
• BarnesDELindahlTRepair and genetic consequences of endogenous DNA base damage in mammalian cellsAnnu Rev Genet20043844547615568983
   PubMed Web of Science ®Google Scholar
• RobertsonABKlunglandARognesTLeirosIDNA repair in mammalian cells: base excision repair: the long and short of itCell Mol Life Sci200966698199319153658
   PubMed Web of Science ®Google Scholar
• AbbottsRMadhusudanSHuman AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancerCancer Treat Rev201036542543520056333
   PubMed Web of Science ®Google Scholar
• WilsonDM3rdKimDBerquistBRSigurdsonAJVariation in base excision repair capacityMutat Res20117111–210011221167187
   PubMed Web of Science ®Google Scholar
• WangJCCellular roles of DNA topoisomerases: a molecular perspectiveNat Rev Mol Cell Biol20023643044012042765
   PubMed Web of Science ®Google Scholar
• PommierYRedonCRaoVARepair of and checkpoint response to topoisomerase I-mediated DNA damageMutat Res20035321–217320314643436
   PubMed Web of Science ®Google Scholar
• CaldecottKWSingle-strand break repair and genetic diseaseNat Rev Genet20089861963118626472
   PubMed Web of Science ®Google Scholar
• ParlantiELocatelliGMagaGDogliottiEHuman base excision repair complex is physically associated to DNA replication and cell cycle regulatory proteinsNucleic Acids Res20073551569157717289756
   PubMed Web of Science ®Google Scholar
• TanYRaychaudhuriPCostaRHChk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genesMol Cell Biol20072731007101617101782
   PubMed Web of Science ®Google Scholar
• ChenDYuZZhuZLopezCDE2F1 regulates the base excision repair gene XRCC1 and promotes DNA repairJ Biol Chem200828322153811538918348985
   PubMed Web of Science ®Google Scholar
• SugasawaKRegulation of damage recognition in mammalian global genomic nucleotide excision repairMutat Res20106851–2293719682467
   PubMed Web of Science ®Google Scholar
• ShuckSCShortEATurchiJJEukaryotic nucleotide excision repair: from understanding mechanisms to influencing biologyCell Res2008181647218166981
   PubMed Web of Science ®Google Scholar
• de BoerJHoeijmakersJHNucleotide excision repair and human syndromesCarcinogenesis200021345346010688865
   PubMed Web of Science ®Google Scholar
• IornsELordCJGrigoriadisAIntegrated functional, gene expression and genomic analysis for the identification of cancer targetsPLoS One200944e512019357772
   PubMed Web of Science ®Google Scholar
• SourisseauTManiotisDMcCarthyAAurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibitionEmbo Mol Med20102413014220373286
   PubMed Web of Science ®Google Scholar
• LiGMMechanisms and functions of DNA mismatch repairCell Res2008181859818157157
   PubMed Web of Science ®Google Scholar
• HewishMLordCJMartinSACunninghamDAshworthAMismatch repair deficient colorectal cancer in the era of personalized treatmentNat Rev Clin Oncol20107419720820177404
   PubMed Web of Science ®Google Scholar
• MartinSALordCJAshworthATherapeutic targeting of the DNA mismatch repair pathwayClin Cancer Res201016215107511320823149
   PubMed Web of Science ®Google Scholar
• MartinSAHewishMLordCJAshworthAGenomic instability and the selection of treatments for cancerJ Pathol2010220228128919890832
   PubMed Web of Science ®Google Scholar
• Mendes-PereiraAMMartinSABroughRSynthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEmbo Mol Med200916–731532220049735
   PubMed Web of Science ®Google Scholar
• MahaneyBLMeekKLees-MillerSPRepair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joiningBiochem J2009417363965019133841
   PubMed Web of Science ®Google Scholar
• KassEMJasinMCollaboration and competition between DNA doublestrand break repair pathwaysFEBS Lett2010584173703370820691183
   PubMed Web of Science ®Google Scholar
• MladenovEIliakisGInduction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathwaysMutat Res20117111–2617221329706
   PubMed Web of Science ®Google Scholar
• McVeyMLeeSEMMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endingsTrends Genet2008241152953818809224
   PubMed Web of Science ®Google Scholar
• de VillartayJPV(D)J recombination deficienciesAdv Exp Med Biol2009650465819731800
   PubMed Web of Science ®Google Scholar
• NussenzweigANussenzweigMCA backup DNA repair pathway moves to the forefrontCell2007131222322517956720
   PubMed Web of Science ®Google Scholar
• KatsuraYSasakiSSatoMInvolvement of Ku80 in microhomology-mediated end joining for DNA double-strand breaks in vivoDNA Repair (Amst)20076563964817236818
   PubMed Web of Science ®Google Scholar
• SchiplerAIliakisGDNA double-strand-break complexity levels and their possible contributions to the probability for error-prone processing and repair pathway choiceNucleic Acids Res201341167589760523804754
   PubMed Web of Science ®Google Scholar
• KavanaghJNRedmondKMSchettinoGPriseKMDNA double strand break repair: a radiation perspectiveAntioxid Redox Signal201318182458247223311752
   PubMed Web of Science ®Google Scholar
• ShiLOberdoerfferPChromatin dynamics in DNA double-strand break repairBiochim Biophys Acta20121819781181922285574
   PubMed Web of Science ®Google Scholar
• MurrayJMStiffTJeggoPADNA double-strand break repair within heterochromatic regionsBiochem Soc Trans201240117317822260685
   PubMed Web of Science ®Google Scholar
• LieberMRThe mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathwayAnnu Rev Biochem20107918121120192759
   PubMed Web of Science ®Google Scholar
• KobayashiJIwabuchiKMiyagawaKCurrent topics in DNA double-strand break repairJ Radiat Res20084929310318285658
   PubMed Web of Science ®Google Scholar
• HelledayTLoJvan GentDCEngelwardBPDNA double-strand break repair: from mechanistic understanding to cancer treatmentDNA Repair (Amst)20076792393517363343
   PubMed Web of Science ®Google Scholar
• WymanCKanaarRDNA double-strand break repair: all’s well that ends wellAnnu Rev Genet20064036338316895466
   PubMed Web of Science ®Google Scholar
• CahillDConnorBCarneyJPMechanisms of eukaryotic DNA double strand break repairFront Biosci2006111958197616368571
   PubMed Web of Science ®Google Scholar
• van den BoschMLohmanPHPastinkADNA double-strand break repair by homologous recombinationBiol Chem2002383687389212222678
   PubMed Web of Science ®Google Scholar
• KarranPDNA double strand break repair in mammalian cellsCurr Opin Genet Dev200010214415010753787
   PubMed Web of Science ®Google Scholar
• FeatherstoneCJacksonSPDNA double-strand break repairCurr Biol1999920R759R76110531043
   PubMed Web of Science ®Google Scholar
• HanadaKIkedaH[Double strand break repair via DNA end-joining]Tanpakushitsu Kakusan Koso199944Suppl 1218381844 Japanese10503021
   PubMedGoogle Scholar
• KanaarRHoeijmakersJHvan GentDCMolecular mechanisms of DNA double strand break repairTrends Cell Biol19988124834899861670
   PubMed Web of Science ®Google Scholar
• TsukamotoYIkedaHDouble-strand break repair mediated by DNA end-joiningGenes Cells1998331351449619626
   PubMed Web of Science ®Google Scholar
• SargentRGBrennemanMAWilsonJHRepair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombinationMol Cell Biol19971712672778972207
   PubMed Web of Science ®Google Scholar
• Saleh-GohariNBryantHESchultzNParkerKMCasselTNHelledayTSpontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaksMol Cell Biol200525167158716916055725
   PubMed Web of Science ®Google Scholar
• LawleyPDPhillipsDHDNA adducts from chemotherapeutic agentsMutat Res19963551–213408781575
   PubMed Web of Science ®Google Scholar
• BoglioloMSchusterBStoepkerCMutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemiaAm J Hum Genet201392580080623623386
   PubMed Web of Science ®Google Scholar
• KumaresanKRSridharanDMMcMahonLWLambertMWDeficiency in incisions produced by XPF at the site of a DNA interstrand cross-link in Fanconi anemia cellsBiochemistry20074650143591436818020456
   PubMed Web of Science ®Google Scholar
• HoTVScharerODTranslesion DNA synthesis polymerases in DNA interstrand crosslink repairEnviron Mol Mutagen201051655256620658647
   PubMed Web of Science ®Google Scholar
• McHughPJSpanswickVJHartleyJARepair of DNA interstrand crosslinks: molecular mechanisms and clinical relevanceLancet Oncol20012848349011905724
   PubMed Web of Science ®Google Scholar
• HinzJMRole of homologous recombination in DNA interstrand crosslink repairEnviron Mol Mutagen201051658260320658649
   PubMed Web of Science ®Google Scholar
• DeansAJWestSCDNA interstrand crosslink repair and cancerNat Rev Cancer201111746748021701511
   PubMed Web of Science ®Google Scholar
• LongDTRaschleMJoukovVWalterJCMechanism of RAD51-dependent DNA interstrand cross-link repairScience20113336038848721719678
   PubMed Web of Science ®Google Scholar
• NicolayNHHelledayTSharmaRABiological relevance of DNA polymerase beta and translesion synthesis polymerases to cancer and its treatmentCurr Mol Pharmacol201251546722122464
   PubMedGoogle Scholar
• YamanakaKLloydRSFunctions of translesion DNA polymerases: implications for cancer risk and opportunities as therapeutic targetsMadhusudanSWilsonDM3rdDNA Repair and Cancer: from Bench to ClinicBoca Raton, USACRC Press2013
   Google Scholar
• McCullochSDKunkelTAThe fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerasesCell Res200818114816118166979
   PubMed Web of Science ®Google Scholar
• HigginsNPKatoKStraussBA model for replication repair in mammalian cellsJ Mol Biol197610134174251255724
   PubMed Web of Science ®Google Scholar
• LongDTKreuzerKNFork regression is an active helicase-driven pathway in bacteriophage T4Embo Rep200910439439919270717
   PubMed Web of Science ®Google Scholar
• HauptSBergerMGoldbergZHauptYApoptosis – the p53 networkJ Cell Sci2003116Pt 204077408512972501
   PubMed Web of Science ®Google Scholar
• PietenpolJAStewartZACell cycle checkpoint signaling: cell cycle arrest versus apoptosisToxicol2002181182475481
   Web of Science ®Google Scholar
• YamtichJNemecAAKehASweasyJBA germline polymorphism of DNA polymerase beta induces genomic instability and cellular transformationPLoS Genet2012811e100305223144635
   PubMed Web of Science ®Google Scholar
• StarcevicDDalalSSweasyJBIs there a link between DNA polymerase beta and cancer?Cell Cycle200438998100115280658
   PubMed Web of Science ®Google Scholar
• BapatAFishelMKelleyMRGoing ape as an approach to cancer therapeuticsAntioxid Redox Signal200911365166818715143
   PubMed Web of Science ®Google Scholar
• BasuBYapTAMolifeLRde BonoJSTargeting the DNA damage response in oncology: past, present and future perspectivesCurr Opin Oncol201224331632422476188
   PubMed Web of Science ®Google Scholar
• Megnin-ChanetFBolletMAHallJTargeting poly(ADP-ribose) polymerase activity for cancer therapyCell Mol Life Sci201067213649366220725763
   PubMed Web of Science ®Google Scholar
• MizuaraiSKotaniHSynthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancementsHum Genet2010128656757520976469
   PubMed Web of Science ®Google Scholar
• DonawhoCKLuoYLuoYABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA- damaging agents in preclinical tumor modelsClin Cancer Res20071392728273717473206
   PubMed Web of Science ®Google Scholar
• OssovskayaVLiLBradleyCShermanBAbstract 2311: activity of BSI-201, a potent poly(ADP-ribose) polymerase (PARP1) inhibitor, alone and in combination with topotecan in human ovarian xenografts99th AACR Annual Meeting2008San Diego, CA
   Google Scholar
• DavarDBeumerJHHamiehLTawbiHRole of PARP inhibitors in cancer biology and therapyCurr Med Chem201219233907392122788767
   PubMed Web of Science ®Google Scholar
• PlummerRLoriganPEvansJFirst and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). In: ASCO Annual Meeting. Atlanta, GAJ Clin Oncol200624 Abstract 8013
   Web of Science ®Google Scholar
• AstraZenecaEfficacy and safety study of olaparib in combination with paclitaxel to treat advanced gastric cancer Available from: http://www.clinicaltrials.gov/ct2/show/NCT01924533. NLM identifier: NCT01924533Accessed August 26, 2013
   Google Scholar
• Sanofi-aventisSanofi-aventis reports top-line results from phase III study with BSI-201 in metastatic triple-negative breast cancer [press release]Paris, FranceSanofi-aventis1272011 Available from: http://en.sanofi.com/Images/13666_20110127_BSI_en.pdfAccessed August 26, 2013
   Google Scholar
• Sanofi-aventisSanofi provides update on phase 3 studies of two investigational compounds [press release]Paris, FranceSanofi-aventis632013 Available from: http://en.sanofi.com/Images/33127_20130603_rdupdate_en.pdfAccessed August 26, 2013
   Google Scholar
• LiuXShiYMaagDXIniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitorClin Cancer Res201218251052322128301
   PubMed Web of Science ®Google Scholar
• GlendenningJTuttAPARP inhibitors – current status and the walk towards early breast cancerBreast201120Suppl 3S12S1922015278
   PubMed Web of Science ®Google Scholar
• RehmanFLLordCJAshworthASynthetic lethal approaches to breast cancer therapyNat Rev Clin Oncol201071271872420956981
   PubMed Web of Science ®Google Scholar
• TumaRSCombining carefully selected drug, patient genetics may lead to total tumor deathJ Natl Cancer Inst2007992015051506150917925530
   PubMedGoogle Scholar
• LordCJAshworthATargeted therapy for cancer using PARP inhibitorsCurr Opin Phamacol200884363369
   PubMed Web of Science ®Google Scholar
• FongPCBossDSYapTAInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med2009361212313419553641
   PubMed Web of Science ®Google Scholar
• MikiYSwensenJShattuckeidensDA strong candidate for the breast and ovarian-cancer susceptibility gene BRCA1Science1994266518266717545954
   PubMed Web of Science ®Google Scholar
• VenkitaramanARCancer susceptibility and the functions of BRCA1 and BRCA2Cell2002108217118211832208
   PubMed Web of Science ®Google Scholar
• GottipatiPVischioniBSchultzNPoly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cellsCancer Res201070135389539820551068
   PubMed Web of Science ®Google Scholar
• DurkaczBWOmidijiOGrayDAShallS(ADP-ribose)n participates in DNA excision repairNature198028357475935966243744
   PubMed Web of Science ®Google Scholar
• StromCEJohanssonFUhlenMSzigyartoCAErixonKHelledayTPoly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediateNucleic Acids Res20113983166317521183466
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYDasBBTrapping of PARP1 and PARP2 by clinical PARP inhibitorsCancer Res201272215588559923118055
   PubMed Web of Science ®Google Scholar
• HelledayTThe underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandingsMol Oncol20115438739321821475
   PubMed Web of Science ®Google Scholar
• BalmanaJDomchekSMTuttAGarberJEStumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancersCancer Discov201111293422586318
   PubMed Web of Science ®Google Scholar
• TuttARobsonMGarberJEOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet2010376973723524420609467
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar
• AstraZenecaOlaparib monotherapy in patients with BRCA mutated ovarian cancer following first line platinum based chemotherapy Available from: http://www.clinicaltrials.gov/ct2/show/NCT01844986. NLM identifier: NCT01844986Accessed June 14, 2013
   Google Scholar
• AstraZenecaOlaparib treatment in BRCA mutated ovarian cancer patients after complete or partial response to platinum chemotherapy Available from: http://www.clinicaltrials.gov/ct2/show/NCT01874353. NLM identifier: NCT01874353Accessed August 26, 2013
   Google Scholar
• DrewYLedermannJAJonesAAbstract 3104: Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2–mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. ASCO Annual Meeting. Chicago, ILJ Clin Oncol2011293104
   Google Scholar
• SchelmanWRSandhuSKMorenoGarcia VFirst-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (SOC). ASCO Annual Meeting. Chicago, ILJ Clin Oncol201129 Abstract 3102
   Web of Science ®Google Scholar
• TurnerNTuttAAshworthAHallmarks of ‘BRCAness’ in sporadic cancersNat Rev Cancer200441081481915510162
   PubMed Web of Science ®Google Scholar
• GiorgettiGGaliziaEBianchiFBrcaness phenotype and methylation of BRCA1 promoter in sporadic breast cancersAnn Oncol200718525217047001
   PubMed Web of Science ®Google Scholar
• HennessyBTTimmsKMCareyMSSomatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancerJ Clin Oncol201028223570357620606085
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• AstraZenecaAstraZeneca updates on olaparib and TC-5214 development programmes [press release]London, UKAstraZeneca12202011 Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20111220-az-updates-olaparib-TC5214-developmentAccessed August 29, 2012
   Google Scholar
• EdwardsSLBroughRLordCJResistance to therapy caused by intragenic deletion in BRCA2Nature200845171821111111518264088
   PubMed Web of Science ®Google Scholar
• SakaiWSwisherEMKarlanBYSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature200845171821116112018264087
   PubMed Web of Science ®Google Scholar
• BouwmanPAlyAEscandellJM53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersNat Struct Mol Biol201017668869520453858
   PubMed Web of Science ®Google Scholar
• LovedayCTurnbullCRamsayEGermline mutations in RAD51D confer susceptibility to ovarian cancerNat Genet201143987988221822267
   PubMed Web of Science ®Google Scholar
• WilliamsonCTKubotaEHamillJDEnhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53Embo Mol Med20124651552722416035
   PubMed Web of Science ®Google Scholar
• SultanaRMcNeillDRAbbottsRSynthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitorsInt J Cancer2012131102433244422377908
   PubMed Web of Science ®Google Scholar
• VilarEBartnikCMStenzelSLMRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancersCancer Res20117172632264221300766
   PubMed Web of Science ®Google Scholar
• KurosawaASaitoSSoSDNA ligase IV and artemis act cooperatively to suppress homologous recombination in human cells: implications for DNA double-strand break repairPLoS One201388e7225323967291
   PubMed Web of Science ®Google Scholar
• LoserDAShibataAShibataAKWoodbineLJJeggoPAChalmersAJSensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repairMol Cancer Ther2010961775178720530711
   PubMed Web of Science ®Google Scholar
• LordCJMcDonaldSSwiftSTurnerNCAshworthAA high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivityDNA Repair (Amst)20087122010201918832051
   PubMed Web of Science ®Google Scholar
• SultanaRAbdel-FatahTAbbottsRTargeting XRCC1 deficiency in breast cancer for personalized therapyCancer Res20137351621163423253910
   PubMed Web of Science ®Google Scholar
• SeoYKinsellaTJEssential role of DNA base excision repair on survival in an acidic tumor microenvironmentCancer Res200969187285729319723658
   PubMed Web of Science ®Google Scholar
• BindraRSGibsonSLMengAHypoxia-induced down-regulation of BRCA1 expression by E2FsCancer Res20056524115971160416357170
   PubMed Web of Science ®Google Scholar
• BindraRSSchafferPJMengAAlterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instabilityAnn N Y Acad Sci2005105918419516382054
   PubMed Web of Science ®Google Scholar
• MartinSAMcCabeNMullarkeyMDNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1Cancer Cell201017323524820227038
   PubMed Web of Science ®Google Scholar
• GuptaAYangQPanditaRKCell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repairCell Cycle20098142198221019502790
   PubMed Web of Science ®Google Scholar
• PucJKeniryMLiHSLack of PTEN sequesters CHK1 and initiates genetic instabilityCancer Cell20057219320415710331
   PubMed Web of Science ®Google Scholar
• ShenWHBalajeeASWangJLEssential role for nuclear PTEN in maintaining chromosomal integrityCell2007128115717017218262
   PubMed Web of Science ®Google Scholar
• MingMHeYYPTEN in DNA damage repairCancer Lett2013319212512922266095
   PubMed Web of Science ®Google Scholar
• YinYShenWHPTEN: a new guardian of the genomeOncogene200827415443545318794879
   PubMed Web of Science ®Google Scholar
• PlanchonSMWaiteKAEngCThe nuclear affairs of PTENJ Cell Sci2008121Pt 324925318216329
   PubMed Web of Science ®Google Scholar
• DedesKJWetterskogDMendes-PereiraAMPTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitorsSci Transl Med201025353ra75
   PubMed Web of Science ®Google Scholar
• McEllinBCamachoCVMukherjeeBPTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitorsCancer Res201070135457546420530668
   PubMed Web of Science ®Google Scholar
• FraserMZhaoHLuotoKRPTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapyClin Cancer Res20121841015102722114138
   PubMed Web of Science ®Google Scholar
• MinamiDTakigawaNTakedaHSynergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cellsMol Cancer Res201311214014823239809
   PubMed Web of Science ®Google Scholar
• ChatterjeePChoudharyGSSharmaAPARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cellsPLoS One201384e6040823565244
   PubMed Web of Science ®Google Scholar
• ForsterMDDedesKJSandhuSTreatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancerNat Rev Clin Oncol20118530230621468130
   PubMed Web of Science ®Google Scholar
• PappasGZumsteinLAMunshiAHobbsMMeynREAdenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacityCancer Gene Ther200714654354917431403
   PubMed Web of Science ®Google Scholar
• SandhuSKSchelmanWRWildingGThe poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialLancet Oncol201314988289223810788
   PubMed Web of Science ®Google Scholar
• MereniukTREl GendyMAMendes-PereiraAMSynthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphataseMol Cancer Ther201312102135214423883586
   PubMed Web of Science ®Google Scholar
• RodriguezAAMakrisAWuMFDNA repair signature is associated with anthracycline response in triple negative breast cancer patientsBreast Cancer Res Treat2010123118919620582464
   PubMed Web of Science ®Google Scholar
• KonstantinopoulosPASpentzosDKarlanBYGene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancerJ Clin Oncol201028223555356120547991
   PubMed Web of Science ®Google Scholar
• MukhopadhyayAElattarACerbinskaiteADevelopment of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitorsClin Cancer Res20101682344235120371688
   PubMed Web of Science ®Google Scholar
• MenearKAAdcockCBoulterR4-[3-(4-cyclopropanecar-bonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1J Med Chem200851206581659118800822
   PubMed Web of Science ®Google Scholar
• LubbersLSRoweBAHodgeLMPISA, a novel pharmacodynamic assay for assessing poly(ADP-ribose) polymerase (PARP) activity in situJ Pharmacol Toxicol Methods201061331932820132901
   PubMed Web of Science ®Google Scholar
• PlummerRJonesCMiddletonMPhase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumorsClin Cancer Res200814237917792319047122
   PubMed Web of Science ®Google Scholar